Alterity Therapeutics Limited (ATHE) - News Archive

Alterity Therapeutics: Pioneering Advances in Neurodegenerative Disease Treatment Amidst Strategic Leadership ChangesMELBOURNE, Australia and SAN FRANCISCO, January 9, 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)...

Alterity Therapeutics Expands Leadership Amid Promising Advances in Neurodegenerative Treatment The Shift in Leadership StrategyIn a significant move on November 18, 2024, Alterity Therapeutics appointed Abby Macnish Ni...

: In recent developments within the realm of pharmaceuticals targeting neurodegenerative disorders, Alterity Therapeutics has caught the spotlight by unveiling a series of promising data presentations at the Internation...

In a significant development in the field of neurodegenerative diseases, Alterity Therapeutics has reported positive interim data from their ATH434-202 Phase 2 clinical trial in Multiple System Atrophy (MSA). The compan...

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - ATH434-201 Trial on Track to Complete in November 2024Alterity Therapeutics, a leading biotech...

Alterity Therapeutics, a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, has recently presented new data showcasing the potential of their investigational drug, A...

Alterity Therapeutics, a foremost biotechnology firm devoted to developing treatment strategies for neurodegenerative ailments, has declared that it will reveal new data points on its promising candidate, ATH434, at the...

In a groundbreaking development, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has successfully secured a A$3.9 million cash refund from the Australian Taxation Office. This significant achievement comes as a r...

The pharmaceutical industry is constantly striving to develop novel therapeutic interventions for various diseases, particularly those with significant unmet medical needs. Alterity Therapeutics is one such company dedi...

In a recent shareholder letter, Alterity Therapeutics highlighted significant advancements in their pipeline, sharing updates on key upcoming milestones. The company has also generated preliminary data from the ATH434-2...

Alterity Therapeutics, a prominent biotechnology company focused on developing transformative therapies for neurodegenerative disorders, has announced a significant breakthrough in the evaluation of Multiple System Atro...